Marshall Wace North America Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$207M |
| 2 |
Pfizer
PFE
|
+$171M |
| 3 |
Johnson & Johnson
JNJ
|
+$140M |
| 4 |
SS&C Technologies
SSNC
|
+$132M |
| 5 |
Microsoft
MSFT
|
+$131M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$158M |
| 2 |
Meta Platforms (Facebook)
META
|
+$120M |
| 3 |
Booking.com
BKNG
|
+$106M |
| 4 |
Merck
MRK
|
+$93.9M |
| 5 |
Idexx Laboratories
IDXX
|
+$92.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.54% |
| 2 | Technology | 21.21% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Industrials | 12.45% |
| 5 | Financials | 7.1% |
Similar funds
Marshall Wace North America's Q3 2019 Portfolio in Review
As of Q3 2019, Marshall Wace North America held 1,695 positions worth $17.6B, up 9.1% from $16.1B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Marshall Wace North America deployed $1.6B of net new capital in Q3 2019, opening 602 new positions and adding to 310 existing holdings. Its largest new stake was Johnson & Johnson: 1,065,531 shares worth $138M.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 28% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $120M trimmed.
- Marshall Wace North America's largest Q3 2019 buy was Johnson & Johnson: 1,065,531 shares worth $138M.
- Marshall Wace North America added most to Apple in Q3 2019, an estimated $207M increase.
- Marshall Wace North America's biggest Q3 2019 reduction was Meta Platforms (Facebook), cutting an estimated $120M.
- Marshall Wace North America fully exited Abbott in Q3 2019, selling an estimated $158M.
- Marshall Wace North America's ten largest holdings make up 18% of its $17.6B portfolio in Q3 2019.
- Marshall Wace North America opened 602 new positions and closed 414 in Q3 2019.
- Marshall Wace North America's portfolio value rose 9.1% quarter-over-quarter to $17.6B.
Based on Marshall Wace North America's 13F filing for Q3 2019, filed 14 Nov 2019.